MITOTANE INCREASES THE BLOOD-LEVELS OF HORMONE-BINDING PROTEINS
MITOTANE INCREASES THE BLOOD-LEVELS OF HORMONE-BINDING PROTEINS
复制标题
DOI：
10.1530/acta.0.1240526
复制
发表时间：
1991-05-01
期刊：
影响因子：
--
通讯作者：
MOOLENAAR, AJ
中科院分区：
文献类型：
--
作者：
VANSETERS, AP;MOOLENAAR, AJ
在 3 名肾上腺皮质癌患者中，研究了长期米托坦治疗对三种激素结合球蛋白和维生素 D 结合蛋白血清水平的影响。 在治疗的第一个月内，皮质醇结合球蛋白增加了两到三倍，与性激素结合球蛋白密切相关。 甲状腺素结合球蛋白和维生素 D 结合蛋白的上升幅度要小得多。 皮质醇结合蛋白升高似乎与皮质醇结合增加有关，而甲状腺素和维生素 D 的结合仍低于正常水平。 停用米托坦后一年内，2 名患者的结合蛋白恢复正常。 这种激素结合蛋白增强的现象使得使用总血清激素水平来监测米托坦对内分泌功能的影响无效，并且可以为米托坦治疗期间皮质醇替代需求增加提供解释。
In 3 patients with adrenocortical carcinoma the effects of long-term mitotane therapy on the serum levels of three hormone-binding globulins and vitamin D-binding protein were studied. Within the first month of treatment cortisol-binding globulin increased two to three times, in close correlation with sex hormone-binding globulin. The rises in thyroxine-binding globulin and vitamin D-binding protein were considerably less. Elevated cortisol-binding protein appeared to be associated with increased binding of cortisol, whereas the binding of thyroxine and vitamin D remained below normal. Binding proteins returned to normal in 2 patients within a year after mitotane discontinuation. This phenomenon of hormone-binding protein enhancement invalidates the use of total serum hormone levels to monitor the effects of mitotane on endocrine function and could provide an explanation for the increased cortisol substitution requirement during mitotane therapy.